{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}],"title":"Positive at day 14 and 21"},{"measurements":[{"groupId":"OG000","value":"1"}],"title":"Negative at all monitoring time points"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"}],"units":"Participants"}],"description":"The levels will be evaluated by flow cytometry and qPCR (in vivo pharmacokinetic profile).","groups":[{"description":"Patients were scheduled to receive a single intravenous (iv) infusion of CD44v6.CAR-transduced autologous lymphocytes at day 0, after lymphodepleting chemotherapy with cyclophosphamide iv (500 mg/m2) and fludarabine iv (30 mg/m2) performed daily from day -5 to day -3\n\nThe dose of iv infused MLM-CAR44.1 T-cells is:\n\nPHASE I: 0.5x10E6/Kg or 1x10E6/Kg or 2x10E6/Kg according to the BOIN design. PHASE IIa: a dose of MLM-CAR44.1 T-cells corresponding to the maximum tolerated dose (MTD).","id":"OG000","title":"MLM-CAR44.1 T-cells Infusion"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"At day 7, 14, 21, 28, 60, 90, 180 from infusion, assessed as day 0","title":"Phase I: The Levels of Circulating MLM-CAR44.1 T-cells in Blood Samples","type":"SECONDARY","unitOfMeasure":"Participants"}